Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The mechanism of cell cycle regulation by v-Src

Abstract

The tyrosine kinase oncoprotein v-Src can overcome the requirements for serum growth factors and anchorage which restrain normal cell growth. Here we investigated the biochemical mechanisms whereby v-Src induces quiescent cells to enter S phase in the absence of serum mitogens. Activating a temperature sensitive v-Src in quiescent cells sequentially induced cyclins D1, E and A and also down regulated p27. We addressed whether p27 down regulation was required to activate cyclin D1/CDK4/6 or cyclin E/CDK2 by engineering cells with inducible p27. Both S phase entry and activation of cyclin/CDKs were inhibited by over expression of p27. Using cells engineered with inducible p16 we showed that Cyclin D/CDK4/6 activity was required for v-Src to increase expression of cyclin A but not cyclin E. To determine which downstream kinases mediated these effects of v-Src we added pharmacological inhibitors of phosphatidylinositol 3-kinase (PI3-K), LY294002 or mitogen activated protein kinase kinase (MEK), U0126. PI3-K was required for v-Src to activate MEK and MEK was required for v-Src to increase expression of cyclins D1 and E. However, the MEK inhibitor prevented p27 protein down regulation whereas the PI3-K inhibitor did not. This was because reduced PI3-K activity lead to proteolytic degradation of p27.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Adachi M, Roussel MF, Havenith K, Sherr CJ . 1997 Blood 90: 126–137

  • Alessandrini A, Chiaur DS, Pagano M . 1997 Leukemia 11: 342–345

  • Allan LA, Duhig T, Read M, Fried M . 2000 Mol. Cell. Biol. 20: 1291–1298

  • Aprelikova O, Xiong Y, Liu ET . 1995 J. Biol. Chem. 270: 18195–18197

  • Aziz N, Cherwinski H, McMahon M . 1999 Mol. Cell. Biol. 19: 1101–1115

  • Blain SW, Montalvo E, Massague J . 1997 J. Biol. Chem. 272: 25863–25872

  • Botz J, Zerfass-Thome K, Spitkovsky D, Delius H, Vogt B, Eilers M, Hatzigeorgiou A, Jansen-Durr P . 1996 Mol. Cell. Biol. 16: 3401–3409

  • Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ . 1999 EMBO J. 18: 1571–1583

  • Cheng M, Sexl V, Sherr CJ, Roussel MF . 1998 Proc. Natl. Acad. Sci. USA 95: 1091–1096

  • Davies SP, Reddy H, Caivano M, Cohen P . 2000 Biochem. J. 351: 95–105

  • Diehl JA, Cheng M, Roussel MF, Sherr CJ . 1998 Genes Dev. 12: 3499–3511

  • Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ . 2000 Mol. Cell. Biol. 20: 9138–9148

  • Duncia JV, Santella JB, Higley CA, Pitts WJ, Wityak J, Frietze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC, Teleha CA, Blom KF, Favata MF, Manos EJ, Daulerio AJ, Stradley DA, Horiuchi K, Copeland RA, Scherle PA, Trzaskos JM, Magolda RL, Trainor GL, Wexler RR, Hobbs FW, Olson RE . 1998 Bioorg. Med. Chem. Lett. 8: 2839–2844

  • Farrell A, Morgan DO . 2000 Mol. Cell. Biol. 20: 749–754

  • Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM . 1998 J. Biol. Chem. 273: 18623–18632

  • Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Doree M, Messier H, Fotedar A . 1996 Oncogene 12: 2155–2164

  • Gu Y, Rosenblatt J, Morgan DO . 1992 EMBO J. 11: 3995–4005

  • Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y . 1994 Genes Dev. 8: 2939–2952

  • Haefner B, Baxter R, Fincham VJ, Downes CP, Frame MC . 1995 J. Biol. Chem. 270: 7937–7943

  • Hall M, Bates S, Peters G . 1995 Oncogene 11: 1581–1588

  • Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC . 1999 Cell 98: 859–869

  • Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N . 1995 Mol. Biol. Cell 6: 387–400

  • Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ . 1995 Mol. Cell. Biol. 15: 2672–2681

  • Hurford Jr RK, Cobrinik D, Lee MH, Dyson N . 1997 Genes Dev. 11: 1447–1463

  • Johnson D, Agochiya M, Samejima K, Earnshaw W, Frame M, Wyke J . 2000 Cell. Death Differ. 7: 685–696

  • Johnson D, Frame MC, Wyke JA . 1998 Oncogene 16: 2017–2028

  • Kaldis P, Solomon MJ . 2000 Eur. J. Biochem. 267: 4213–4221

  • LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E . 1997 Genes Dev. 11: 847–862

  • Ladha MH, Lee KY, Upton TM, Reed MF, Ewen ME . 1998 Mol. Cell. Biol. 18: 6605–6615

  • Le Cam L, Polanowska J, Fabbrizio E, Olivier M, Philips A, Ng Eaton E, Classon M, Geng Y, Sardet C . 1999 EMBO J. 18: 1878–1890

  • Lee KM, Saiz JE, Barton WA, Fisher RP . 1999a Curr. Biol. 9: 441–444

  • Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines III GK, Webster M, Muller WJ, Brugge JS, Davis RJ, Pestell RG . 1999b J. Biol. Chem. 274: 7341–7350

  • McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G . 1999 Mol. Cell. Biol. 19: 1981–1989

  • Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M . 1999 Genes Dev. 13: 1181–1189

  • Morisaki H, Ando A, Nagata Y, Pereira-Smith O, Smith JR, Ikeda K, Nakanishi M . 1999 Exp. Cell. Res. 253: 503–510

  • Nishiwaki E, Turner SL, Harju S, Miyazaki S, Kashiwagi M, Koh J, Serizawa H . 2000 Mol. Cell. Biol. 20: 7726–7734

  • Odajima J, Matsumura I, Sonoyama J, Daino H, Kawasaki A, Tanaka H, Inohara N, Kitamura T, Downward J, Nakajima K, Hirano T, Kanakura Y . 2000 J. Biol. Chem. 275: 24096–24105

  • Poon RY, Hunter T . 1995 Science 270: 90–93

  • Resnitzky D, Gossen M, Bujard H, Reed SI . 1994 Mol. Cell. Biol. 14: 1669–1679

  • Reynisdottir I, Massague J . 1997 Genes Dev. 11: 492–503

  • Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM, Stampfer MR . 1997 Mol. Cell. Biol. 17: 2458–2467

  • Schulze A, Zerfass K, Spitkovsky D, Middendorp S, Berges J, Helin K, Jansen-Durr P, Henglein B . 1995 Proc. Natl. Acad. Sci. USA 92: 11264–11268

  • Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R . 2000 Oncogene 19: 5419–5427

  • Vlahos CJ, Matter WF, Hui KY, Brown RF . 1994 J. Biol. Chem. 269: 5241–5248

  • White MK, Weber MJ . 1988 Mol. Cell. Biol. 8: 138–144

  • Wyke AM, Cushley W, Wyke JA . 1993 Cell. Growth Differ. 4: 671–678

  • Wyke AW, Frame MC, Gillespie DA, Chudleigh A, Wyke JA . 1995 Cell Growth Differ. 6: 1225–1234

Download references

Acknowledgements

We are grateful to Steve Coats, Amgen, USA for p27 cDNA; Gordon Peters, ICRF for p16 construct; Sybille Mittnacht, ICR, London for bacteria expressing GST-pRb-C, CST for antibody against phospho-T160 CDK2. D Riley was funded by Association for International Cancer Research project grant number 98284 and The Sylvia Aitkin Trust, NO Carragher and MC Frame were funded by the Cancer Research Campaign.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John A Wyke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riley, D., Carragher, N., Frame, M. et al. The mechanism of cell cycle regulation by v-Src. Oncogene 20, 5941–5950 (2001). https://doi.org/10.1038/sj.onc.1204826

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204826

Keywords

This article is cited by

Search

Quick links